Our sister site, Drug Delivery Business News, reports today that Stelo — Dexcom’s FDA-cleared over-the-counter glucose biosensor — is now its first product to use GenAI-enabled technology to produce weekly insights.
Dexcom leveraged Google Cloud’s Vertex AI platform and Gemini models to build the GenAI platform. The technology offers users more personalized tips, recommendations and education related to diet, exercise and sleep. The Stelo app then contextualizes these findings for the user.
The new platform analyzes individual health data patterns. It could reveal a direct association between lifestyle choices and glucose levels and provide actionable insights to improve metabolic health.
Get the full story at our sister site, Drug Delivery Business News.
